Abstract
Preapproval studies cannot tell us all that must be known about the safety of a drug. For this reason, post-marketing surveillance (PMS) is a crucial activity. Monitoring of adverse drug reaction reports for developing signals and conducting epidemiologic studies to test such signals are the two main activities encompassed by PMS. The FDA is giving high priority to both of these activities and is seeking to strengthen international communications in this area.
Get full access to this article
View all access options for this article.